Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential vanilloid 3 (TRPV3) is a **Ca²⁺-permeable non-selective cation channel** that is primarily expressed in skin keratinocytes but is also present in other organs such as the brain, colon, testis, heart, lung, and liver[2][4][5]. It functions as a **temperature-sensitive sensor** involved in the perception of warm temperatures, **mediates Ca²⁺ signaling** essential for skin physiology (including barrier formation, wound healing, and hair growth), and participates in **pain and itch sensation**, making it a prominent therapeutic target for skin-related disorders such as pruritus, atopic dermatitis, and Olmsted syndrome[2][5]. Structurally, TRPV3 is a tetrameric channel (with occasional pentameric assemblies under specific conditions), composed of six transmembrane domains per subunit and belonging to the broader TRP channel superfamily[2][6][8]. Numerous modulators (natural and synthetic) have been identified, with ongoing efforts to develop selective TRPV3 agonists and antagonists for therapeutic use[2][3][4]. Dysregulation of TRPV3 activity has been linked to inflammatory skin diseases, chronic itching, and the pathophysiology of certain cancers[2][3].
Agonists bind to distinct sites, causing conformational changes that open the cation channel and allow Ca²⁺ influx, mediating downstream signaling[4]. Inhibitors such as osthole competitively block agonist sites or induce non-conducting conformations, reducing activity and associated responses such as itching or cell proliferation[3]. Some agents induce unique channel states, such as DPBA-induced pore dilation, leading to altered ion permeability[6].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential vanilloid 3 (TRPV3).